Acurx Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis
Acurx Pharmaceuticals, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). High-risk, high-reward antibiotic developer in an underserved market segment facing typical clinical-stage biotech volatility and capital needs. Market cap as of February 2026 was $5.35 million with a stock price of $2.11, reflecting pre-revenue clinical-stage risks. While the company has FDA QIDP designation and Fast Track status for ibezapolstat.
What is Acurx Pharmaceuticals, Inc.'s industry? Acurx Pharmaceuticals, Inc. (acurxpharma.com) operates in Pharmaceuticals. AskCyborg classifies Acurx Pharmaceuticals, Inc. under Pharmaceuticals in its company registry.
Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The company develops antibiotic candidates w...
Cyborg Score thesis
High-risk, high-reward antibiotic developer in an underserved market segment facing typical clinical-stage biotech volatility and...
Read the full analyst-debate transcript →Get the Latest Acurx Pharmaceuticals, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAcurx Pharmaceuticals, Inc. Overview
Pro stress-test →Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The company develops antibiotic candidates with a Gram-positive selective spectrum that blocks the bacterial enzyme DNA polymerase IIIC, inhibiting DNA replication and leading to Gram-positive bacterial cell death.
Strategic Profile
Pro stress-test →Its R&D pipeline targets Gram-positive bacteria, including Clostridioides difficile, MRSA, vancomycin resistant Enterococcus, drug-resistant Streptococcus pneumoniae, and B. anthracis. The company began a Phase 2 clinical trial in August 2026 with expected completion in November 2027, with plans for Phase 3 advancement in recurrent CDI.
Competitive Landscape
Pro stress-test →Acurx targets Gram-positive pathogens including CDI, MRSA, VRE, DRSP, and anthrax through a proprietary DNA polymerase IIIC inhibition mechanism. Direct competitors include traditional antibiotic developers and specialty infectious disease biotech firms, though few companies focus specifically on the Gram-positive selective spectrum approach.
Industry Context
Acurx Pharmaceuticals, Inc. operates in Pharmaceuticals.
Key facts
Founded: 2017 · Headquarters: Staten Island, New York, US · Employees: Not publicly disclosed · Revenue: Pre-revenue, clinical-stage company · Market cap: $5.35M (as of February 2026)